Summary The expression of bcl-2 was studied in normal ovanres and in ovarian tumours by immunohistochemical analysis. Normal epithelium was strongly stained in all nine examined ovaries. In comparison. all tumour groups showed a substantially decreased tumour cell expression of the same order of magnitude. Thus. benign tumour cells were weakly stained in two and unstained in two samples, while the remaining eight showed strong expression. Of ten borderline samples. one was unstained and five had weakly and four strongly bcl-2 positive tumour cells. Finally. 24 of 50 malignant tumours showed strong staining, while weak or no expression in tumour cells was found in 16 and 10 samples respectively. The reduced staining deviated significantly from normal ovary for both borderline (P = 0.02) and malignant groups (P = 0.01). Tumour cell staining with the bcl-2 antibody was significantly reduced when tumour mass had to be left behind compared with those with no visible remaining tumour (P = 0.03 and 0.003 for weakly and strongly stained tumours respectively). The expression of bcl-2 in malignant tumour cells was inversely correlated with the expression of p53. Bcl-2 expression was correlated with survival with significantly reduced survival in weakly (P = 0.02) and unstained (P<0.001) groups compared with those patients having strongly stained malignant tumour cells. This correlation between the presence of bcl-2 and survival was maintained in the subgroups of patients with advanced disease or with residual tumour bulk and was also the case in patients having p53-positive tumours. Our results indicate an inhibitory role of bcl-2 in development and progression of ovarian tumours.
Epithelial ovarian cancer is the leading cause of death in gynaecological malignancy (Petterson, 1991) . Treatment is aggressive primary debulking surgery followed by chemotherapy in advanced disease. Although several different clinical trials have been carried out, only a marginal increase in survival has been obtained. Our lack of basic knowledge of the tumour biology underlying this disease presents a major obstacle to improving treatment, as well as to establishing treatment modalities based on aetiological and pathogenetic evidence. Only recently have studies on the role of growth factors in ovarian cancer been carried out, and hitherto two growth factor receptors of prognostic value have been found which appear to be involved in some facet of ovarian tumour development (Slamon et al., 1989; Henriksen et al., 1993) .
While much effort has concentrated on examining mechanisms of increased proliferation in cancer development, the regulation of physiological cell death has only recently come into focus. Cell suicide is a well-known fundamental feature in different biological settings (for recent reviews see Raff, 1992; Wyllie 1993; Kerr and Winterford, 1994) . The ultrastructural changes which deviate from the necrotic process were described in 1972 and the process termed apoptosis (Kerr et al., 1972) . It provides an efficient mechanism for eliminating cells that are unwanted for some reason and may furthermore be of significance for keeping cell numbers at constant levels in different organs.
Bcl-2 is an oncoprotein, which apparently inhibits apoptosis (McDonnell et al., 1989; Hockenbery et al., 1990) . In a few studies on protein expression in various disorders both inhibitory and stimulatory properties towards carcinogenesis were indicated (Castle et al., 1993; Colombel et al., 1993; Leek et al., 1994) . In a recent study in non-small-cell lung cancer bcl-2 expression was correlated with survival (Pezella et al., 1993 (Colombel et al., 1993; Pezella et al., 1993; Leek et al., 1994) . The results are summarised in Table II Expression was graded 0-2 corresponding to no staining, weak or strong staining (P =0.02 and 0.01 for bcl-2 = 0 or bcl-2 = I compared with bcl-2 =2 in the borderline and malignant groups vs the normal ovaries). substantial fraction of cases compared with ovarian epithelium was observed in the tumour groups, and the differences were significant for both the borderline (P = 0.02) and malignant groups (P = 0.01).
Subsequently, tumour staining was compared with the known risk factors stage, residual tumour bulk and differentiation (Table III) . While no relation between the presence of bcl-2 and dissemination or differentiation of tumours could be detected, decreased expression was observed significantly more often in patients with residual tumour tissue after primary operation compared with radically operated ones (P = 0.03 and P = 0.003 for weakly and strongly stained groups respectively).
Expression of bcl-2 in the stroma in benign, borderline and malignant neoplasms Positive stromal staining was observed in most samples in all groups. Normal ovaries were strongly stained in the cortical parts and only weakly in the core. The tumour groups showed varying staining with no difference between them (results not shown).
Comparison of bcl-2 expression in malignant ovarian tumour cells with survival
The decreased expression of bcl-2 in ovarian neoplasms compared with ovarian epithelium led us to examine its potential correlation with survival. As shown in Figure 5 there was a stepwise and highly significant correlation with survival. Among the group whose tumours stained strongly, 81% were alive at the end of the observation period while for those Expression was graded 0-2 corresponding to no staining, weak or strong staining (P = 0.03 and P = 0.003 for bcl-2 = I and 2 respectively in those having residual tumour mass compared with patients macroscopically tumour-free after operation).
with weakly stained and unstained neoplasms, 52% (P=0.02) and 20% (P<0.001) were alive respectively. The difference was even significant between the weakly and unstained groups (P= 0.03). This correlation is of the same magnitude as stage (Figure 6 ), residual tumour bulk ( Figure  7 ) and the new biological prognostic parameter plateletderived growth factor alpha (PDGF-() receptor (Henriksen et al., 1993) . The strength of bcl-2 as a prognostic marker was tested by relating staining to survival in the subgroups with advanced disease (Figure 6 ) or residual tumour bulk (Figure 7 ). For patients in stages III or IV the decreased survival was retained for unstained vs strongly stained groups (Figure 6 , P= 0.002). When patients with residual tumour bulk were stratified for bcl-2 expression in tumour cells significance was found between strongly and unstained groups ( Figure 7 , P = 0.03). (Figure 5 ). The strength was further evaluated by studying the subgroups of patients with advanced disease or residual tumour bulk, both of which are strong clinical prognostic parameters. In both these subgroups, too, survival was significantly correlated with bcl-2 staining, which underscores an independent role in tumour development and,or progression. In line with our results are the recent observations in non-small-cell lung cancer (Pezella et al., 1993) and breast carcinoma (Silvestrini et al., 1994) , where expression of this oncoprotein correlated with survival.
In other recent works the staining in tumour cells was decreased in breast carcinoma compared with normal breast epithelium, but no survival data were reported (Leek et al., 1994; Nathan et al., 1994) . High levels of bcl-2 in cells derived from several cancers resulted in profound growth inhibition while a COOH-terminal deletion mutant of bcl-2 had no effect (Pietenpol et al., 1994) . In contrast, in human prostate cancers, and especially those refractory to androgen treatment, a stronger bcl-2 staining than corresponding epithelium was noticed and led the authors to suggest a relation to androgen-resistant prostate cancer (Colombel et al., 1993 (Chiou et al., 1994) . While bcl-2 diverted the activity of wild-type p53 from apoptosis to induction of growth arrest, it did not affect the localisation or the levels of p53 indicating an effect downstream of the tumour-suppressor gene product. In other recent reports the same group presented evidence for a p53-inducible decrease of bcl-2 and increase of bax expression (Miyashita et al., 1994a; Selvakumaran et al., 1994) and for a p53-dependent negative response element in the bcl-2 gene (Miyashita et al., 1994b) . This might be expected to result in an inverse expression of p53 and bcl-2, and this has been reported in normal tissues (Pezella et al.. 1994) as well as in mammarian tumours (Silvestrini et al., 1994) and in the present work, too, an inverse correlation was found. However, while an interaction with bcl-2 function is supposed to exist with the wild-type form of p53, not much is known of a corresponding function with the different mutational forms of the protein. In one report overexpression of mutant p53 could induce down-regulation of bcl-2 both at mRNA and protein level (Haldar et al., 1993) . Whether this is valid in our material remains to be elucidated.
The number of patients in our study does not allow a multivariate analysis. To elucidate the possible significance of bcl-2 independently of p53, the correlation with survival in the p53-positive group was examined. As seen in Figure 8 a significant correlation between bcl-2 expression and survival was still detectable which underlines that the observed correlation between bcl-2 expression and survival is not secondary to mutational inactivation of p53. In the group negatively stained for p53 the material was too small to make similar statistical estimations.
In conclusion, we have reported a strong epithelial staining of bcl-2 in ovaries and a reduced tumour cell immunoreactivity in benign, borderline and malignant epithelial ovarian tumours. Overall, the expression in malignant tumours strongly correlated with enhanced survival, which was also observed in subgroups of patients with advanced disease or residual tumour bulk as well as in patients having p53-positive tumours, indicating an independent role in ovarian carcinogenesis. Acowedgements
